All In Biotech

Drug Trial Radar · NCT01718288

Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)

Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb), Unsuitable or Suitable to Surgical Revascularization / Endovascular With Reference to the Change of Pain-free Walking Distance and Other Endpoints

Last checked: Nov 20, 2026Latest source record: Oct 31, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Nov 2006

Primary completion

Mar 2011

Study completion Apr 2012

Sponsor

Lead sponsor
Fadoi Foundation, ItalyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the possibility of optimization of therapy with prostanoids (iloprost), in patients with Fontaine's stage IIb severe chronic ischemia, both in patients eligible for surgery both in patients for which it is only possible medical therapy

Conditions

  • Peripheral Arterial Disease

Interventions

  • iloprostDrug

    The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2). For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost. The 4 groups: 1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment 1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment 2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment 2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment

  • Standard Treatment (aspirin.....),Drug

    The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD. correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure of PFWD(pain-free walking distance)in patients with 2b stage PADTime frame: 13 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Internal Medicine, Hospital "Policlinico"

    Bari, Italy

  • Angiology, Hospital "Ferrarotto - Alessi"

    Catania, Italy

  • Internal Medicine, Hospital "Pugliese - Ciaccio"

    Catanzaro, Italy

  • Internal Medicine, Hospital of Fermo

    Fermo, Italy

  • Vascular Surgery, Hospital "Galliera"

    Genoa, Italy

  • Internal Medicine, Hospital Civile

    Legnano, Italy

  • Internal Medicine, "Madonna delle Grazie" Hospital

    Matera, Italy

  • Internal Medicine, Hospital "Fatebenefratelli"

    Naples, Italy

  • Surgery Dept., Hospital " San Giovanni Bosco"

    Naples, Italy

  • Internal Medicine, Hospital "Bianchi Melacrino Morelli"

    Reggio Calabria, Italy

  • Internal Medicine, Hospital Policlinico Campus Biomedico

    Rome, Italy

  • Internal Medicine, Hospital "Fondazione Circolo Macchi"

    Varese, Italy

  • Internal Medicine, Hospital "Jazzolino"

    Vibo Valentia, Italy

  • Angiology, Hospital "G. Fucito"

    Mercato San Severino, Salerno, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.